| Both sides previous revisionPrevious revision | Both sides next revision |
pharmaceutical_companies:pfizer [2022/12/13 12:21]
pamela [Pfizer Recommends Hydroxychloroquine for Covid-19] | pharmaceutical_companies:pfizer [2023/01/10 17:37] (current)
liam [Payments to Individuals] |
|---|
| | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | | | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | |
| | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | | | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | |
| | | [[:Nigel Crawford]] | Research | Unknown | "Investigator on a number of epidemiological surveillance research and vaccine safety research. Funds received by employer", [[:Murdoch Children's Research Institute]] (MCRI).((//Australian Technical Advisory Group on Immunisation - Conflict of Interest.// Australia Government Department of Health and Aged Care. Retrieved October 24, 2022, from https://web.archive.org/web/20221024032912/https://www.health.gov.au/sites/default/files/atagi-conflict-of-interest-disclosures.pdf)) | |
| | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | | | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | |
| | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | | | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | |
